Hematology, Transfusion and Cell Therapy最新文献

{"title":"POLYRADICULOPATHY FOLLOWING CAR T-CELL THERAPY FOR LYMPHOID MALIGNANCIES, DIAGNOSTIC CHALLENGES: A REPORT OF 3 CASES","authors":"Alfadil Haroon, Nawaf Aldawsari, Naeem Chaudhri, Ali Alahmari, Mahmoud Aljurf, Syed O Ahmed, Abdulwahab Albabtain","doi":"10.1016/j.htct.2025.103922","DOIUrl":"10.1016/j.htct.2025.103922","url":null,"abstract":"<div><h3>Objective</h3><div>Neurotoxicity is a serious but incompletely understood complication of CAR T-cell therapy. here we highlight presentation and diagnostic challenges of non-CNS CAR T-cell therapy complication.</div></div><div><h3>Case series</h3><div><em>Case 1:</em> A 43-year-old female with relapsed DLBCL stage IVB without CNS involvement underwent Axi-Cel CAR T-cell therapy, developing grade I CRS responded to tocilizumab. On day +15, developed diplopia and 6<sup>th</sup> nerve palsy MRI suggestive CNS lymphomatous infiltration, managed with dexamethasone and intrathecal MTX with a PET scan on day 30 showing CMR. Subsequently, she had limbs weakness with EMG/NCS confirming polyradiculopathy CSF showing high protein but negative for infection, malignant cells and autoimmune. Treatment included methylprednisolone, plasmapheresis, and IVIG, leading to slight improvement. Day 60 PET-CT revealed cervical and lumbar nerve roots neuritis, and by day 90, biopsy-confirmed disease relapse. She had partial response to glofitamab, unfortunately, she passed away four months post-CAR T-cell therapy.</div><div><em>Case 2:</em> A 38-year-old male with primary refractory stage III DLBCL received Axi-Cel after lymphodepletion with Flu/Cy. On day +1, grade I CRS developed and was treated with tocilizumab and dexamethasone. By day +4, he exhibited ICANS grade IV with confusion and seizures, managed with methylprednisolone, anakinra, and lorazepam. CSF showed high protein but no infection or malignant cells. MRI suggested viral encephalitis, and acyclovir was started. Extubated on day +8, but showed lower limb weakness (0/5 power) and urinary retention. Spinal MRI showed intramedullary T2 changes. IVIG was given on day +11, and physical therapy started. By day +16, he could stand; MRI normalized by day +29. PET-CT on day +32 showed a very good partial response. The patient was able to walk and discharged on day +39 with ongoing recovery.</div><div><em>Case 3:</em> A 36-year-old male with CML transformed to B-cell ALL with CNS involvement refractory to triple IT chemotherapy received IT thiotepa, complicating with lower limb weakness and sphincter loss. NCS confirmed L5 radiculopathy; MRI and CSF were negative for blasts or CNS disease. Post-Brexu-cel infusion (day +5 to +7), he developed CRS grade I, treated with Tocilizumab, followed by worsening lower limb weakness and sensory loss. MRI revealed new cauda equina leptomeningeal enhancement; NCS confirmed bilateral polyradiculopathy. CSF showed high protein but no blasts or infections. IVIG, methylprednisolone, anakinra and IT MTX-hydrocortisone improved symptoms. MRD assessment on day +30 was negative repeated MRI brain and spine showed resolution of leptomeningeal enhancement.</div></div><div><h3>Conclusion</h3><div>With the increasing use of CAR T-cell therapy, rare side effects, such as sensory-motor polyradiculopathy, are emerging. These cases underscore the challenges of diagnosing and managing non","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103922"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROGRESSION OF POLYCYTHEMIA VERA TO ACUTE MYELOID LEUKEMIA FOLLOWING LONG-TERM HYDROXYUREA THERAPY: A CASE STUDY","authors":"Bengisu Ece Duman ,&nbsp;Melis Selin Kadıoğlu ,&nbsp;Halil İbrahim Yüksel ,&nbsp;Birol Güvenç","doi":"10.1016/j.htct.2025.103929","DOIUrl":"10.1016/j.htct.2025.103929","url":null,"abstract":"<div><div>Polycythemia Vera (PV) is a chronic Myeloproliferative Neoplasm (MPN) with a well-documented risk of progression to Aute Myeloid Leukemia (AML), particularly in patients undergoing prolonged cytoreductive therapy. This report details the case of a 66-year-old male diagnosed with PV five years prior, initially managed with hydroxyurea. Over time, he developed progressive pancytopenia, ultimately leading to a diagnosis of AML. Following leukemic transformation, the patient was treated with azacitidine, a hypomethylating agent commonly utilized in myeloid malignancies. However, hematologic response was minimal, and disease progression ensued. Molecular analysis identified AML-associated mutations, which are implicated in disease evolution, therapeutic resistance, and poor prognosis. The transition from PV to AML represents a critical clinical challenge, significantly worsening patient outcomes. While hydroxyurea remains a widely used first-line therapy for PV, its potential role in leukemic transformation continues to be debated. Azacitidine, although a viable therapeutic option for post-MPN AML, frequently yields limited and non-durable responses, particularly in patients with high-risk genetic alterations. This case underscores the necessity of vigilant monitoring in PV patients receiving long-term cytoreductive therapy to enable early detection of leukemic progression. Alternative treatment approaches, including JAK inhibitors, interferon therapy, and early hematopoietic stem cell transplantation in eligible patients, may play a role in reducing leukemic transformation risk. Further research is essential to enhance the understanding of post-MPN AML pathogenesis and optimize treatment strategies to improve patient survival.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103929"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RITUXIMAB WITH INVOLVED FIELD IRRADIATION FOR EARLY-STAGE DIFFUSE LARGE CELL LYMPHOMA","authors":"Vera Kovalskaya ,&nbsp;Natalya Falaleeva ,&nbsp;Stanislav Shklyaev ,&nbsp;Andrey Chelmakov ,&nbsp;Ludmila Grivtsova ,&nbsp;Marwa Abdelgawad ,&nbsp;Ahmed Mubarek","doi":"10.1016/j.htct.2025.103895","DOIUrl":"10.1016/j.htct.2025.103895","url":null,"abstract":"<div><h3>Objective</h3><div>Efficacy and safety of Involved Field (IF) radiotherapy in combination for anti-CD20 antibody Rituximab (MabThera) and Involved field Radiotherapy for early-stage Diffuse Large Cell lymphoma (DLBCL) in a prospective, single-arm multicenter study.</div></div><div><h3>Methodology</h3><div>Forty-five stage I–II FL patients received 8 cycles of Rituximab (375  mg/m²) and IF irradiation (30/40 Gy). Progression-Free Survival (PFS) 1-year from treatment start is the primary endpoint. Secondary endpoints were complete response rates, toxicity, quality of life with protocol defined visits up to month 15.</div></div><div><h3>Results</h3><div>For the primary endpoint, PFS at 1-year was 85% for the intention-to-treat set. Long-term data were captured in selected sites and evaluated as post hoc analysis in the Per Protocol (PP) set: PFS was 78% at 1-year with a median follow-up of 15 months, respectively. There were 17/45 recurrences in the PP set, of which 14 were outside the radiation volume only. There were 9 serious adverse events (3 related to the therapy) during the first 15 months.</div></div><div><h3>Conclusion</h3><div>IF radiotherapy combined with Rituximab is well tolerated and highly efficient with low rates of recurrence in the first years in early-stage DLBCL. The efficacy is comparable with more aggressive therapy approaches without compromising the quality of life and maintains for an extended follow-up of more than 3 years.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103895"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral post-surgical complications in patients with hemophilia and von Willebrand disease","authors":"Luisa Catarina Porfirio de Sousa,&nbsp;Elanne Cristina Garcia da Costa Félix,&nbsp;Wagner Hespanhol,&nbsp;Raquel dos Santos Pinheiro","doi":"10.1016/j.htct.2025.103936","DOIUrl":"10.1016/j.htct.2025.103936","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prevalence of post-surgical complications in patients with hemophilia and von Willebrand disease.</div></div><div><h3>Methods</h3><div>A prospective, cross-sectional study with descriptive and exploratory data analysis was conducted at the outpatient clinic of the Arthur de Siqueira Cavalcanti State Institute of Hematology (Hemorio). The sample included 26 patients who underwent tooth extraction following the protocols of the Brazilian Ministry of Health.</div></div><div><h3>Results</h3><div>The prevalence of post-surgical complications identified in the study was 26.07 %, with 15.38 % of cases presenting bleeding after extraction.</div></div><div><h3>Conclusion</h3><div>The prevalence of postoperative complications found in this study was notably higher in patients with von Willebrand disease, followed by those with severe hemophilia.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103936"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological characterization of chronic myeloid leukaemia patients at an oncologic centre: A retrospective observational study","authors":"Ana Maria Meireles ,&nbsp;Rita Calisto ,&nbsp;Maria José Bento ,&nbsp;Pedro Martinho Gouveia ,&nbsp;Susana Bizarro ,&nbsp;Manuel Teixeira ,&nbsp;Cláudia Moreira ,&nbsp;Ana Espírito Santo ,&nbsp;Mário Mariz","doi":"10.1016/j.htct.2025.103935","DOIUrl":"10.1016/j.htct.2025.103935","url":null,"abstract":"<div><h3>Background</h3><div>The chronic myeloid leukaemia population, treatment patterns and responses in Portugal are unknown. The aim of this study is to describe these features in a Portuguese reference centre.</div></div><div><h3>Methods</h3><div>A retrospective cohort study included patients with chronic myeloid leukaemia, treated between 2012 and 2022 at the Instituto Português de Oncologia of Porto. Data were obtained from the Cancer Registry of the institution and clinical records. Variables included demographic data, treatments administered, responses (hematologic, cytogenetic, major and deep molecular responses), adverse events, and survival. Patients without available data, those treated in a clinical trial context, and those admitted only for hematopoietic transplantation were excluded.</div></div><div><h3>Results</h3><div>Ninety-nine patients were included in this study, with a median age of 52 years (range: 7–84 years) at diagnosis. The first-line treatment was imatinib in 96 patients however 33 required second-line with dasatinib, and 17 discontinued treatment while maintaining response. Regarding responses, 95 (96 %) patients achieved cytogenetic response, 90 (94 %) achieved major molecular response, and 71 (72 %) achieved deep molecular response. At three months, the early molecular response rate was 77 %. At 12 months of treatment, of the 67 patients with response evaluation, 93 % achieved complete cytogenetic response and 49 % major molecular response. Both imatinib and dasatinib were well tolerated. The median follow-up was eight years. The five-year overall survival was 96 %.</div></div><div><h3>Conclusion</h3><div>This study is the first to characterize chronic myeloid leukaemia patients at a Portuguese centre. The patient characteristics, responses, and overall survival were within the expected range according to the literature. This study confirms the good prognosis of chronic myeloid leukaemia and the good responses using imatinib as first-line treatment.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103935"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A RARE CASE OF DIFFUSE LARGE B-CELL LYMPHOMA PRESENTING WITH CHRONIC GASTROINTESTINAL SYMPTOMS: A DIAGNOSTIC CHALLENGE","authors":"Bulut Sat ,&nbsp;Burak Demir ,&nbsp;Birol Güvenç","doi":"10.1016/j.htct.2025.103909","DOIUrl":"10.1016/j.htct.2025.103909","url":null,"abstract":"<div><div>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, but primary Gastrointestinal (GI) involvement remains relatively rare. Diagnosing GI lymphoma is challenging due to its nonspecific symptoms, such as chronic abdominal pain, weight loss, and anemia, which can mimic benign gastrointestinal disorders. This case highlights a patient with persistent GI symptoms who was ultimately diagnosed with DLBCL, underscoring the importance of considering lymphoma in cases of unexplained GI complaints and treatment-resistant anemia. A 45-year-old female presented with eight months of persistent epigastric pain, bloating, and indigestion. Despite undergoing multiple endoscopic and colonoscopic evaluations, no active pathology was identified. Due to persistent symptoms and treatment-resistant anemia, a bone marrow biopsy was performed, which was reported as normocellular. Over the next two months, she experienced unintentional weight loss of 25 kg raising suspicion for an underlying malignancy. FDG-PET/CT was performed, revealing diffuse thickening of the bowel wall in the left abdomen and periumbilical region, increased metabolic activity in mesenteric lymph nodes, mild bone marrow uptake, and abnormal activity in the anal canal. Given the concern for a lymphoproliferative disorder, the patient underwent diagnostic laparoscopy followed by excisional mesenteric biopsy, which confirmed Diffuse Large B-Cell Lymphoma (DLBCL) of non-germinal center B-cell phenotype. This case emphasizes the importance of recognizing lymphoma as part of the differential diagnosis in chronic gastrointestinal complaints, particularly when associated with unexplained anemia and significant weight loss despite normal endoscopic findings. It also underscores the critical role of PET/CT in identifying occult lymphoma and the necessity of excisional biopsy for definitive diagnosis in cases where conventional diagnostic methods fail to reveal a cause. Early recognition and diagnosis of GI-DLBCL are crucial for timely treatment and improved patient outcomes.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103909"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACUTE LYMPHOBLASTIC LEUKEMIA DIAGNOSED FOUR YEARS AFTER HSCT IN A BETA THALASSEMIA PATIENT: A CLINICAL CASE","authors":"Samira Hasanova,&nbsp;Huseyn Kerimov,&nbsp;Avesta Allahverdiyeva,&nbsp;Azer Kerimov,&nbsp;Nargiz Aliyeva,&nbsp;Seher İsmayilova","doi":"10.1016/j.htct.2025.103907","DOIUrl":"10.1016/j.htct.2025.103907","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Beta thalassemia is an inherited blood disorder caused by defective synthesis of the beta chains of hemoglobin. This results in the production of ineffective red blood cells, leading to anemia and a severe reduction in the ability to transport oxygen to organs and tissues. In some cases, patients with beta thalassemia, due to prolonged treatment processes and other factors, may develop malignant hematologic disorders. This case presentation describes a patient diagnosed with beta thalassemia major who developed Acute Lymphoblastic Leukemia (ALL) four years after undergoing Hematopoietic Stem Cell Transplantation (HSCT).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;A patient diagnosed with beta thalassemia major, registered at the Thalassemia Center (TC), underwent allogeneic HSCT in 2020 and was later diagnosed with T-cell Acute Lymphocytic Leukemia (T-ALL) four years post-transplant.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A 19-year-old male patient was diagnosed with beta thalassemia major at the age of one year. He has been under regular follow-up at the Thalassemia Center since the age of six. At seven years old, he was officially diagnosed with “Beta Thalassemia Major” (HbA2 ‒ 3.9%; HbF ‒ 57.1%) and has since been on a transfusion regimen with chelation therapy. On February 23, 2020, he underwent an allogeneic bone marrow transplantation from his HLA 10/10 matched sibling using the BU/Flu/CY/ATG/TT myeloablative conditioning regimen. Post-transplant chimerism analysis showed 93% donor cells. The patient was regularly monitored at the TC-HSCT outpatient clinic.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Medical history&lt;/h3&gt;&lt;div&gt;The patient was born from his mother’s third pregnancy and third delivery.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Two siblings from previous pregnancies did not survive.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• He was born at term with a birth weight of 3500g.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• He had incomplete routine vaccinations.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• He had a history of measles and chickenpox infections.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• The family denies a history of tuberculosis or venereal skin diseases.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• One healthy sibling lives at home.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Parents are not consanguineous.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• The father was diagnosed with Hodgkin lymphoma two months ago and started treatment.&lt;/div&gt;&lt;div&gt;On November 5, 2024, the patient presented with extensive bruising and petechiae over his entire body. His general condition was severe, and laboratory findings were:&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Leukocytes (L): 284.32 × 10³/µL&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Hemoglobin (Hb): 121 g/L&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Platelets (Tr): 30 × 10⁹/L&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Blast cells: 80%&lt;/div&gt;&lt;div&gt;The patient was hospitalized and diagnosed with T-ALL.&lt;/div&gt;&lt;div&gt;Flow Cytometry Findings:&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• SSC/CD45 analysis revealed 90% blast cells in the CD45 low region.&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Blast cells expressed T-lymphoid markers (CD2+, CD3+, CD5+, CD7+, CD38+).&lt;/div&gt;&lt;div&gt; &lt;!--&gt;• Based on clinical and laboratory findings","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103907"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UPDATES ON HODGKIN DISEASE","authors":"Valeh Huseynov","doi":"10.1016/j.htct.2025.103871","DOIUrl":"10.1016/j.htct.2025.103871","url":null,"abstract":"<div><div>Hodgkin Lymphoma (HL) is a B-cell malignancy accounting for approximately 10% of all lymphoma cases and 5% of lymphoma-related mortalities. Incidence increases in younger adults and those above 55-years of age and has a bimodal distribution. Approximately 95% of all HL cases are diagnosed as classical Hodgkin Lymphoma (cHL) and 5% as Nodular Lymphocyte Predominant B-cell Lymphoma (NLPBL). Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups of classical HL. Risk Stratification An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by Positron Emission Tomography (PET) scan, are used to optimize therapy. Risk‐Adapted Therapy Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early‐stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved‐field radiation therapy, whereas those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. However, newer agents including brentuximab vedotin and anti‐PD‐1 antibodies are now standardly incorporated into frontline therapy. Management of Relapsed/Refractory Disease High‐Dose Chemotherapy (HDCT) followed by an Autologous Stem Cell Transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD‐1 blockade, non‐myeloablative allogeneic transplant or participation in a clinical trial should be considered. The AETHERA study (NCT01100502) shows that Brentuximab Vedotin (BV) improves Progression-Free Survival (PFS) after ASCT in patients with Refractory or Relapsed HL (R/R HL). For patients who relapse after ASCT, BV, and anti-PD-1, monoclonal antibodies were considered incurable, and their outcome is rather dismal, with a median Overall Survival (OS) of 2-years. For Refractory or Relapsed cHL (R/R cHL) patients who have failed both ASCT and BV, Chimeric Antigen Receptor T-cell (CAR-T) therapy offers a new therapeutic option.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103871"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"WHICH IS THE BEST TREATMENT FOR AML WITH RESTRICTED RESOURCES","authors":"Mipsang Lama","doi":"10.1016/j.htct.2025.103870","DOIUrl":"10.1016/j.htct.2025.103870","url":null,"abstract":"<div><div>AML itself is one of the worst prognostic hematological malignancies which has to be managed timely, adequately and aggressively to get on top of it. Such, kind of patients will need intensive chemotherapy therapy (3+7, Flag IDA) followed by allogeneic SCT. That is why it is challenging to manage such cases in resource limited setting. Due to constant development of new drugs treatment of such patients with azacytidine and venetoclax have been lot easier. With these drugs we are being able to put patients in remission with less toxicities, and low cost as compared to intensive chemotherapy.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103870"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144534611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T cell therapy-related lumbosacral polyradiculopathy with myelitis and stiff person syndrome with response to intravenous immunoglobulin and corticosteroids in a patient with acute lymphoblastic leukemia","authors":"Hannah Goulart ,&nbsp;Kevin Elmore ,&nbsp;Stephen Scelsa ,&nbsp;Daniel Park ,&nbsp;Alla Keyzner ,&nbsp;Uroosa Ibrahim","doi":"10.1016/j.htct.2025.103932","DOIUrl":"10.1016/j.htct.2025.103932","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103932"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}